NCT00005674COMPLETEDanonymous

Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]

Sponsor

Source record

National Center for Research Resources (NCRR)

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Creatine's mechanism involves improving energy metabolism in cells, potentially mitigating overactive nerve activity and abnormal cellular metabolism associated with ALS.

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis

Intervention

Source record

Creatine

Source & freshness

Source record

NCT ID

NCT00005674

Original source

ClinicalTrials.gov

Source last updated

Jun 24, 2005

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00005674

Title

Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]

Sponsor

National Center for Research Resources (NCRR)

Status

COMPLETED

Phase

Phase 2

Condition raw

Amyotrophic Lateral Sclerosis

Condition normalized

Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Creatine's mechanism involves improving energy metabolism in cells, potentially mitigating overactive nerve activity and abnormal cellular metabolism associated with ALS.

Target normalized

Creatine's mechanism involves improving energy metabolism in cells, potentially mitigating overactive nerve activity and abnormal cellular metabolism associated with ALS.

Interventions

Creatine

Public preview

Source record

The clinical trial of creatine in ALS represents a significant opportunity in a market with a high unmet need, as there are currently no effective treatments for ALS. With the trial's completion and initial safety data indicating tolerability, there is potential for further development and commercialization. The competitive landscape includes existing therapies like riluzole, but creatine's novel mechanism may provide a complementary approach. Stakeholders should assess the potential for partnerships or licensing agreements, particularly with organizations focused on neurodegenerative diseases.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT00005674

Status

COMPLETED

Phase

Phase 2

Sponsor

National Center for Research Resources (NCRR)

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJun 24, 2005

Internal syncJun 13, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00005674

Indication

Amyotrophic Lateral Sclerosis

Modality

small molecule

Target

Creatine's mechanism involves improving energy metabolism in cells, potentially mitigating overactive nerve activity and abnormal cellular metabolism associated with ALS.

Intervention

Creatine

Source record